Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

ClinicalTrials.gov ID: NCT01023308

Public ClinicalTrials.gov record NCT01023308. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Study identification

NCT ID
NCT01023308
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
767 participants

Conditions and interventions

Interventions

  • Panobinostat Drug
  • Bortezomib Drug
  • Dexamethasone Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 20, 2009
Primary completion
Jul 29, 2015
Completion
Jul 29, 2015
Last update posted
Mar 16, 2020

2009 – 2015

United States locations

U.S. sites
38
U.S. states
22
U.S. cities
37
Facility City State ZIP Site status
Novartis Investigative Site Phoenix Arizona
Novartis Investigative Site Anaheim California 92801
Novartis Investigative Site Concord California 94520
Novartis Investigative Site Los Angeles California 90027
Novartis Investigative Site San Diego California 92120
Novartis Investigative Site Stanford California 94304
Novartis Investigative Site Boca Raton Florida 33486
Novartis Investigative Site Lake Worth Florida 33467
Novartis Investigative Site Miami Shores Florida 33138
Novartis Investigative Site Athens Georgia 30607
Novartis Investigative Site Atlanta Georgia 30322
Novartis Investigative Site Marietta Georgia 30060
Novartis Investigative Site Marywood Illinois 60153
Novartis Investigative Site Quincy Illinois 62301
Novartis Investigative Site New Orleans Louisiana 70115
Novartis Investigative Site Baltimore Maryland 21229
Novartis Investigative Site Rockville Maryland 20850
Novartis Investigative Site Boston Massachusetts 02215
Novartis Investigative Site Southfield Michigan
Novartis Investigative Site Edina Minnesota 55435
Novartis Investigative Site Minneapolis Minnesota 55404
Novartis Investigative Site Columbia Missouri 65201
Novartis Investigative Site East Orange New Jersey 07018-1095
Novartis Investigative Site Mount Kisco New York 10549
Novartis Investigative Site Durham North Carolina 27710
Novartis Investigative Site Bismarck North Dakota 58501
Novartis Investigative Site Dayton Ohio 45429
Novartis Investigative Site Middletown Ohio 45042
Novartis Investigative Site Pittsburgh Pennsylvania 15224
Novartis Investigative Site East Providence Rhode Island 02915
Novartis Investigative Site Nashville Tennessee 37203
Novartis Investigative Site Nashville Tennessee 37232
Novartis Investigative Site Amarillo Texas 79106
Novartis Investigative Site Houston Texas 77030
Novartis Investigative Site Kennewick Washington 99336
Novartis Investigative Site Seattle Washington 98104
Novartis Investigative Site Walla Walla Washington 33962
Novartis Investigative Site Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 172 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01023308, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2020 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01023308 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →